期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 175, 期 10, 页码 1569-1579出版社
WILEY
DOI: 10.1111/bph.14181
关键词
-
资金
- ISCIII
- FEDER
- Instituto de Salud Carlos III (ISCIII)
- RETICS Programme (RIER: Red de Investigacion en Inflamacion y Enfermedades Reumaticas) via Instituto de Salud Carlos III (ISCIII) [RD16/0012/0014]
- Instituto de Salud Carlos III [PIE13/00024, PI14/00016, PI17/00409, PI15/00681, CB16/11/00226, PI16/01870, CP15/00007]
- Research Executive Agency of the European Union in the framework of MSCA-RISE Action of the H2020 Programme [734899]
- European Commission Framework 7 programme (EU FP7) [HEALTH.2012.2.4.5-2, 305815]
- Innovative Medicines Initiative Joint Undertaking [115770]
- European Union
Obesity has reached epidemic proportions in the Western society and is increasing in the developing world. It is considered as one of the major contributors to the global burden of disability and chronic diseases, including autoimmune, inflammatory and degenerative diseases. Research conducted on obesity and its complications over the last two decades has transformed the outdated concept of white adipose tissue (WAT) merely serving as an energy depot. WAT is now recognized as an active and inflammatory organ capable of producing a wide variety of factors known as adipokines. These molecules participate through endocrine, paracrine, autocrine or juxtacrine crosstalk mechanisms in a great variety of physiological or pathophysiological processes, regulating food intake, insulin sensitivity, immunity and inflammation. Although initially restricted to metabolic activities (regulation of glucose and lipid metabolism), adipokines currently represent a new family of proteins that can be considered key players in the complex network of soluble mediators involved in the pathophysiology of immune/inflammatory diseases. However, the complexity of the adipokine network in the pathogenesis and progression of inflammatory diseases has posed, since the beginning, the important question of whether it may be possible to target the mechanism(s) by which adipokines contribute to disease selectively without suppressing their physiological functions. Here, we explore in depth the most recent findings concerning the involvement of adipokines in inflammation and immune responses, in particular in rheumatic, inflammatory and degenerative diseases. We also highlight several possible strategies for therapeutic development and propose that adipokines and their signalling pathways may represent innovative therapeutic strategies for inflammatory disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据